JHOP - December 2020 Vol 10, No 6

Anna Kempke, PharmD, BCOP, BCPS; Shawna Kraft, PharmD, BCOP; Mariana Castells, MD, PhD; Rajan Ravikumar, MD; Catherine Van Poznak, MD

Original Article

Outcomes for Patients Receiving Ibrutinib with or without Antifungal Therapy

Kori Daniels, PharmD, BCOP; Arpita Gandhi, PharmD, BCOP; Locke Bryan, MD; Amber Clemmons, PharmD, BCOP

The Safety Profile of Mini-Dose Methotrexate for Graft-versus-Host Disease Prophylaxis: Is There a Place for Folinic Acid Rescue?

Loriel J. Solodokin, PharmD, BCOP; Amir Steinberg, MD, FACP; Erin Moshier, MS

Evaluation of Inpatient Oral Chemotherapy: An Academic Medical Center Experience

Vincent J. Cascone, PharmD, BCOP; Kane M. Hosmer, PharmD, BCOP; Zahra Mahmoudjafari, PharmD, BCOP; David W. Henry, MS, RPh, BCOP, FASHP; Dennis W. Grauer, MS, PhD

Vaccination Rates in Patients with Hematologic Cancers After Hematopoietic Stem-Cell Transplant: A Single-Center Retrospective Study

Hiba Ahmad, PharmD, BCOP; Sarah Perreault, PharmD, BCPS, BCOP; Dayna McManus, PharmD, BCPS-AQ ID; Francine Foss, MD; Iris Isufi, MD; Stuart Seropian, MD; Jeffrey Topal, MD

HOPA Abstracts

HOPA 2020 Abstracts, Part IV

FDA Updates

Danyelza First Drug FDA Approved for High-Risk Neuroblastoma in the Bone and Bone Marrow

Gavreto, a New RET Inhibitor, FDA Approved for Metastatic NSCLC with RET fusions

Onureg FDA Approved for Adults with AML in Remission

Gavreto Now Approved for Thyroid Cancer with RET Fusions

Keytruda plus Chemotherapy Approved for Unresectable or Metastatic Triple‑Negative Breast Cancer

Keytruda Approved for Relapsed or Refractory Classical Hodgkin Lymphoma

Opdivo plus Yervoy First Immunotherapy Approved for Unresectable Malignant Pleural Mesothelioma

FDA Approves First Prostate-Specific Membrane Antigen–Targeted PET Imaging Drug for Prostate Cancer